Literature DB >> 8058587

Comparative effects of felbamate and other compounds on N-methyl-D-aspartic acid-induced convulsions and lethality in mice.

R D Sofia1, R Gordon, M Gels, W Diamantis.   

Abstract

Felbamate and selected compounds were evaluated for their ability to protect against N-methyl-D-aspartic acid (NMDA)-induced convulsions and lethality in mice. Convulsions produced by intracerebroventricular administration of NMDA (0.8 micrograms per mouse) were antagonized by felbamate, phenytoin, carbamazepine, phenobarbital, valproate, diazepam, 2-amino-5-phosphonovalergic acid (APV), dextromethorphan and ketamine. NMDA (350 mg kg-1 intraperitoneally) produced 100% lethality in mice. Felbamate, phenytoin, and phenobarbital were ineffective in preventing NMDA-induced lethalities, whereas diazepam, APV, ketamine and dextromethorphan were the most potent compounds in preventing lethalities. Any relationship between the protective effects of felbamate against NMDA-induced seizures and competitive or non-competitive antagonism of NMDA receptor sites, however, cannot be established until further experimentation is carried out.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8058587     DOI: 10.1016/1043-6618(94)80037-5

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  3 in total

Review 1.  Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024.

Authors:  António F Ambrósio; Patrício Soares-Da-Silva; Caetana M Carvalho; Arsélio P Carvalho
Journal:  Neurochem Res       Date:  2002-02       Impact factor: 3.996

2.  Chronic carbamazepine administration reduces N-methyl-D-aspartate receptor-initiated signaling via arachidonic acid in rat brain.

Authors:  Mireille Basselin; Nelly E Villacreses; Mei Chen; Jane M Bell; Stanley I Rapoport
Journal:  Biol Psychiatry       Date:  2007-07-12       Impact factor: 13.382

3.  Behavioral effects of ketamine and toxic interactions with psychostimulants.

Authors:  Tamaki Hayase; Yoshiko Yamamoto; Keiichi Yamamoto
Journal:  BMC Neurosci       Date:  2006-03-16       Impact factor: 3.288

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.